Lexicon Pharmaceuticals, Inc. (LXRX) income statement
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3082% above fair value
$1.72−0.06 (-3.37%)
Close on Nov 18, 2026Market cap $765.32MP/E –Yield –
Lexicon Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 99.1%
- Operating margin
- -131.4%
- Net margin
- -147.4%
- Return on equity, FY2025
- -39.7%
Financial strength
- Current ratio
- 13.37
- Debt to equity
- 0.29
- Debt to assets
- 20.6%
- Cash to current liabilities
- 278.3%
Valuation
- P/E ratio
- –
- Price to sales
- 18.46
- Price to book
- 4.39
- Dividend yield
- –
See a number that looks wrong?